Group 1 - China Biopharmaceutical announced a successful collaboration progress with Merck on LM-299, expecting to receive a $300 million technology transfer milestone payment soon [1] - The technology transfer for LM-299 was completed in July 2025, with Merck confirming the milestone payment in the third quarter [1] - CSPC Pharmaceutical reached an exclusive licensing agreement with Madrigal for the GLP-1 receptor agonist SYH2086, with a total deal value of up to $20.75 billion [2] Group 2 - Eli Lilly's drug Mounjaro (tirzepatide injection) received approval from China's National Medical Products Administration for a new indication to improve blood sugar control in adults with type 2 diabetes [3] - Hualan Pharmaceutical expects a profit of approximately RMB 1.184 billion for the first half of the year, following the successful transfer of commercialization tasks for Huataning [4] - WuXi AppTec reported a 101.92% increase in net profit to RMB 8.561 billion for the first half of the year, with revenue growth of 20.64% to RMB 20.799 billion [5] Group 3 - Heng Rui Medicine signed a collaboration agreement with GSK to advance innovative therapies in respiratory, autoimmune, inflammation, and oncology fields, with a potential total value of approximately $12 billion [6][7] - GSK will pay Heng Rui a $500 million upfront payment, with potential future milestone payments based on successful development and sales [7]

Core Viewpoint - Hualing Pharmaceutical reported a profit of approximately 1.184 billion RMB in the first half of the year, marking its first profit since its listing, a significant turnaround from a loss of 140 million RMB in the same period last year [1][2]. Group 1: Financial Performance - The profit growth is largely attributed to a one-time gain from terminating an exclusive promotion agreement with Bayer, resulting in a reversal of unamortized contract liabilities amounting to 1.2435 billion RMB [2][4]. - Hualing Pharmaceutical's revenue is expected to be scrutinized in the future, as the one-time gain does not indicate sustainable growth [4]. - The company's sales of its main product, Huatangning, reached approximately 1.764 million boxes with a net sales revenue of about 217.4 million RMB, reflecting a 111.8% increase compared to the same period last year [6][10]. Group 2: Product and Market Strategy - Hualing Pharmaceutical's main product, Huatangning, is currently the only commercialized drug, targeting type 2 diabetes patients [8]. - The company has successfully transitioned to a self-managed sales model, having built its own sales team for the first time, which has contributed to the doubling of product sales [6][7]. - The gross profit margin increased to approximately 54.2% in the first half of the year, up from 46.5% in the same period last year, attributed to improved production efficiency and reduced unit production costs [6]. Group 3: Future Outlook - Hualing Pharmaceutical aims to achieve a sales net income of 1 billion RMB by 2027, indicating a long-term growth strategy [7]. - The company is in the early stages of its commercial sales journey, with significant potential for growth in the diabetes medication market [10].

与单纯增加胰岛素剂量相比，联合使用替尔泊肽可显著改善血糖控制、减少胰岛素用量、降低体重，且不增加低血糖风险，为胰岛素治疗效果不佳的患者提 供了更优的治疗选择。 对于新增联合疗法适应症的获批，北京医院国家老年医学中心内分泌科主任郭立新教授表示："在研究中，替尔泊肽在既往胰岛素治疗的中国2型糖尿病患者 中，与安慰剂相比，在血糖控制和体重减轻方面展现出具有临床意义的显著改善，且未增加低血糖风险。" 复旦大学附属中山医院内分泌科主任李小英教授此前告诉第一财经记者，GLP-1药物联合胰岛素控制糖尿病是临床上正在探索的一个具有潜力的方向。 胰岛素为何不可或缺？ 7月28日，礼来公司的GLP-1类药物替尔泊肽注射液（商品名：穆达峰）又添新增适应症——联合胰岛素治疗，用于在饮食控制和运动基础上，改善成人2型 糖尿病（T2DM）患者的血糖控制。 此前，替尔泊肽已经在中国获批三项适应症，包括用于成人2型糖尿病的血糖控制，长期体重管理以及阻塞性睡眠呼吸暂停。 在我国，针对糖尿病的治疗，胰岛素的使用率相对较高，但患者整体血糖控制率仍不理想，且胰岛素治疗常伴随低血糖风险及体重增加等不良反应。 与单纯增加胰岛素剂量相比，联合使用替尔泊肽 ...

Core Viewpoint - Hualing Pharmaceutical Technology (Shanghai) Co., Ltd. reported a profit of approximately 1.184 billion yuan for the first half of the year, marking its first profitable period [1] Group 1: Financial Performance - The company sold approximately 1.764 million boxes of Huadongning, generating a sales revenue of about 217 million yuan in the first half of the year [1] - In comparison, the sales volume for the same period in 2024 was about 846,000 boxes, with a sales revenue of approximately 102.7 million yuan, indicating a sales growth of 111.8% while maintaining the same price per box [1] - As of June 30, 2025, the gross profit was around 118 million yuan, with a gross margin of approximately 54.2%, compared to a gross profit of about 47.8 million yuan and a gross margin of 46.5% in 2024 [1] Group 2: Strategic Insights - The increase in gross margin is attributed to improved production efficiency and higher output, leading to a decrease in unit production costs [1] - The CEO, Dr. Chen Li, emphasized the strong growth momentum of Huadongning and the establishment of a sales team that accelerates market penetration, instilling confidence for future profitability [1] - The company plans to continue exploring market potential in personalized diabetes treatment and complications through research and development innovation and capacity enhancement [1]

Group 1 - The company, HuaLing Pharmaceutical, has released a positive profit forecast, reporting a profit of approximately RMB 1.184 billion for the current reporting period [1] - Following the termination of the exclusive promotion service agreement with Bayer on January 1, 2025, the company has recognized RMB 1.244 billion of unamortized contract liabilities as income, contributing to the revenue for the group [1] - The successful transfer of the commercialization task for Huatangning® in mainland China and improvements in production efficiency have led to an increase in gross profit margin [1] Group 2 - In the first half of the year, the company sold approximately 1,764,000 boxes of Huatangning®, generating net sales of about RMB 217 million, compared to 846,000 boxes and RMB 103 million in net sales during the same period in 2024, reflecting a sales increase of 111.8% [1] - The expected gross profit for the six months ending June 30, 2025, is approximately RMB 118 million, a significant increase from RMB 47.8 million in the same period in 2024 [2] - The gross profit margin is projected to rise from 46.5% in 2024 to about 54.2% for the six months ending June 30, 2025, primarily due to improved production efficiency and reduced unit production costs [2]

Group 1 - The company expects a profit of approximately 1.184 billion RMB for the six months ending June 30, 2025, driven by improved commercialization efficiency and sales growth [1][2] - The termination of the exclusive promotion service agreement with Bayer on January 1, 2025, allowed the company to recognize previously unamortized contract liabilities of 1.244 billion RMB as revenue, contributing to profit [1] - The successful transfer of commercialization tasks for Huadongning® in China and improvements in production efficiency have led to an increase in gross profit margin [1][2] Group 2 - The company sold approximately 1.764 million boxes of Huadongning® with net sales of about 217 million RMB for the six months ending June 30, 2025, reflecting a 111.8% increase in sales compared to 846,000 boxes and 103 million RMB in the same period of 2024 [1] - The expected gross profit for the six months ending June 30, 2025, is about 118 million RMB, significantly up from 47.8 million RMB in 2024, with the gross margin increasing from 46.5% to approximately 54.2% [2] - The transition from loss to substantial profit in the first half of 2025 indicates the successful implementation of the company's commercialization strategy, enhancing market confidence [2]

Company News - China Railway Construction (01186.HK) reported a new contract amount of approximately 1,056.17 billion yuan for the first half of the year, a year-on-year decrease of 4.04% [2] - China Metallurgical Group (01618.HK) announced a new contract amount of 548.2 billion yuan for the first half of the year, down 19.1% year-on-year [2] - Sichuan Chengyu Expressway (00107.HK) won the bid for the G5 Jingkun Expressway Chengdu to Ya'an section expansion project, with a total investment of approximately 28.548 billion yuan [2] - Road King Infrastructure (01098.HK) reported total property sales of 5.232 billion yuan for the first half of the year, a decrease of 28.37% year-on-year [2] - Amax Holdings (00880.HK) plans to acquire a property in Hengqin for 724.2 million yuan to diversify its business portfolio [2] - Chaoyue Eye Hospital (02219.HK) signed a construction contract for the first phase of its comprehensive medical facility project, with a contract value of 223 million yuan [2] - Bay Area Development (00737.HK) reported total toll revenue of 243 million yuan for June, a year-on-year decrease of 4% [2] - Decent Pharmaceuticals-B (06996.HK) received approval for its drug, Hivio®, for the second-line treatment of multiple myeloma in China [2] - Tianchen Holdings (01201.HK) plans to invest 30 million yuan to establish a joint venture in Shenzhen for new energy heavy truck charging stations [2] Performance Summary - WuXi AppTec (02359.HK) reported mid-year revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit of 8.561 billion yuan, up 101.92% year-on-year [3] Earnings Announcements - China Nonferrous Mining (01258.HK) issued a profit warning, expecting mid-term net profit of approximately 258 million USD, a year-on-year increase of about 18% [4] - Hualing Pharmaceutical-B (02552.HK) issued a profit warning, expecting mid-term net profit of approximately 1.184 billion yuan, turning from loss to profit [4] - Little Yellow Duck (02250.HK) issued a profit warning, expecting mid-term revenue to increase by over 30% year-on-year [4] - Qingci Games (06633.HK) issued a profit warning, expecting mid-term net profit to increase by approximately 78%-130% year-on-year [4] - Goodbaby International (01086.HK) issued a profit warning, expecting mid-term net profit to decrease by approximately 40%-50% year-on-year [4] - Qianhai Health (00911.HK) issued a profit warning, expecting mid-term net profit to decrease by approximately 60%-70% year-on-year [4] - Tianan Health (00383.HK) issued a profit warning, expecting mid-term net profit to decrease to approximately 7 million to 17 million HKD [4] - Pacific Network (00543.HK) issued a profit warning, expecting mid-term net loss of approximately 5 million to 15 million yuan [4] Buyback and Increase Dynamics - HSBC Holdings (00005.HK) repurchased 348,700 shares for approximately 35.487 million HKD at a price of 101.4-102 HKD [3] - China Eastern Airlines (00670.HK) repurchased 2.5 million shares for approximately 7.4983 million HKD at a price of 2.97-3.03 HKD [3] - Founder Holdings (00418.HK) canceled a total of 17.9962 million shares that had been repurchased [3]

Core Viewpoint - The company anticipates a significant turnaround in profitability, projecting a profit of approximately RMB 1,184.1 million for the six months ending June 30, 2025, compared to a loss of about RMB 142.0 million in the same period of 2024 [1][2] Group 1: Financial Performance - The expected profit increase is attributed to the successful transfer of commercialization tasks for Huadongning in China and improvements in production efficiency, leading to a higher gross margin [2] - For the six months ending June 30, 2025, the company sold approximately 1,764,000 boxes of Huadongning, generating a net sales revenue of about RMB 217.4 million, compared to 846,000 boxes and RMB 102.7 million in the same period of 2024, reflecting a sales growth of 111.8% [2] - The anticipated gross profit for the six months ending June 30, 2025, is approximately RMB 117.8 million, a significant increase from RMB 47.8 million in 2024, driven by increased sales and improved gross margin [2] Group 2: Operational Changes - The company has fully taken over the commercialization tasks for Huadongning in mainland China and has appointed a sales leader with over 20 years of experience in diabetes drug commercialization to lead its sales and marketing efforts [1] - The gross margin is expected to rise from 46.5% in 2024 to approximately 54.2% for the six months ending June 30, 2025, primarily due to enhanced production efficiency and increased output, resulting in lower unit production costs [2]

（於開曼群島註冊成立的有限公司） （股份代號：2552） 正面盈利預告 本公告乃由華領醫藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交 易所有限公司證券上市規則第13.09條及香港法例第571章證券及期貨條例第XIVA 部之內幕消息條文而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 HUA MEDICINE 華領醫藥 1 本公司仍在確定本集團於本報告期的中期業績，而本公告所載資料為基於本集團 管理賬目的初步統計數字及初步評估，未經本公司核數師審核或審閱。股東及潛 在投資者務請參閱將於2025年8月公佈的本報告期本公司中期業績公告。 承董事會命 行政總裁兼執行董事 陳力博士 香港，2025年7月28日 於本公告日期，董事會成員包括執行董事陳力博士、林潔誠先生及 張怡博士；非執行董事Robert Taylor Nelsen先生；以及獨立非執行董事 William Robert Keller先生、徐耀華先生及張耀樑先生。 2 本公司董 ...

Summary of Key Points Core Viewpoint - As of July 14, a total of 138 stocks reached their 52-week highs, indicating a strong performance in the market, with notable leaders including Green Heart Group Holdings, OK Blockchain, and Pearl River Steel Pipe [1]. Group 1: Top Performers - Green Heart Group Holdings (02999) achieved a closing price of 0.013 with a peak of 0.017, marking a 70.00% increase [1]. - OK Blockchain (01499) closed at 0.680, reaching a high of 0.690, reflecting a 48.39% rise [1]. - Pearl River Steel Pipe (01938) had a closing price of 0.335 and a peak of 0.340, resulting in a 33.33% increase [1]. Group 2: Other Notable Stocks - Weishi Jiajie (00856) saw a 32.01% increase, closing at 8.870 with a high of 11.300 [1]. - Cloud Intelligence (09678) reached a high of 520.000, closing at 510.000, which is a 20.99% increase [1]. - China Chengtong Development Group (00217) closed at 0.165 with a peak of 0.166, marking a 14.48% rise [1]. Group 3: Additional Stocks with Significant Increases - Sihuan Pharmaceutical (00460) closed at 1.380, reaching a high of 1.430, which is a 14.40% increase [1]. - Taited Pharmaceutical (03880) had a closing price of 36.950 and a peak of 37.400, reflecting a 13.85% rise [1]. - Beihai Kangcheng-B (01228) closed at 0.850 with a high of 0.960, resulting in a 12.94% increase [1].